Results 141 to 150 of about 11,011 (206)

Costs of Single Maintenance and Reliever Therapy vs Traditional Therapy for Asthma.

JAMA Netw Open
Pham T, Barker AR, Eisenstein SA, Jost E, Volerman A, Chauhan K, Brownson RC, McBride T, Huffman MD, Sumino K, Gerald LB, Castro M, Dixon AE, Krings JG.   +13 more
europepmc   +1 more source

Budesonide/formoterol for pediatric asthma: bridging the gap between evidence and practice in Maintenance and Reliever Therapy. [PDF]

Front Med (Lausanne)
Tian FX, Wang XP, Wang DM.
europepmc   +1 more source

Response to: Letter to the Editor Regarding 'Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study'. [PDF]

Adv Ther
Alcázar-Navarrete B, Figueira-Gonçalves JM, Corregidor-García C, Fitas E, Sánchez-Covisa J.   +4 more
europepmc   +1 more source

Analysis of Current Status and Influencing Factors of Inhaler Treatment Adherence Among COPD Patients. [PDF]

Int J Chron Obstruct Pulmon Dis
Jin Z, Ba B, Zhang W, Yang Z, Wang X.
europepmc   +1 more source

Efficacy and immune-inflammatory modulation of combined glucocorticoid and anti-tuberculosis therapy in patients with bronchial asthma and pulmonary tuberculosis. [PDF]

Am J Transl Res
Fang L, Liao X, Lin J.
europepmc   +1 more source

Real-World Effectiveness and Safety of Single Inhaler Triple Therapy with Beclometasone/ Formoterol/ Glycopyrronium in Moderate to Severe Asthma: TriMaximize Study. [PDF]

J Asthma Allergy
Gessner C, Russell REK, Greulich T, Lommatzsch M, Suppli Ulrik C, Pohl W, Plaza V, Bourdin A, Kupczyk M, Braido F, Piraino A, Scaffidi-Argentina U, Bogoevska V, Trinkmann F, TriMaximize Core team, TriMaximize Core team, Akyildiz B, Fritz C, Grickschat V, Hahn A, Baumeister S, Richards J, Kisiel J, Krogh N.   +23 more
europepmc   +1 more source

Comparative effectiveness and safety of fluticasone-based versus beclometasone-based single-inhaler triple therapies in patients with chronic obstructive pulmonary disease: a population-based cohort study. [PDF]

Int J Clin Pharm
Dong YH, Pan SW, Chen MC, Chen CY, Tsai NH, Kumamaru H.   +5 more
europepmc   +1 more source

Rethinking asthma therapy, part 1: transdermal delivery of β₂-agonists. [PDF]

J Pharm Pharm Sci
Correa J, Brogden NK.
europepmc   +1 more source

Effectiveness and Safety of Glycopyrronium-Formoterol-Budesonide Triple Therapy in Chronic Obstructive Pulmonary Disease (AIR-FORCE): An Open-Label Multi-Centric Phase 4 Study. [PDF]

Adv Respir Med
Nath AR, Kumar A, Bhate AS, Mehrotra B, Rai DK, Barge VK, Bhojwani D, Bhagat S, Bhushan S, Patil S, Barkate H.   +10 more
europepmc   +1 more source

Implementation of a stepped anti-inflammatory reliever therapy intervention with budesonide-formoterol 160/4·5 mcg by Turbuhaler versus usual care for adults presenting during exacerbations of obstructive lung disease suggestive of asthma or chronic obstructive pulmonary disease in a resource-limited setting: an open-label, cluster randomised trial. [PDF]

EClinicalMedicine
Fox GJ, Chau NQ, Yen PN, Van Giap V, Li Q, Jan S, Huang E, Negin J, Anh NT, Reddel H, Marks GB.   +10 more
europepmc   +1 more source